Clinical implications of differential functional capacity between tissue-specific human mesenchymal stromal/stem...

Area of Science:

• Regenerative Medicine
• Cell Biology
• Biotechnology

Background:

• Mesenchymal stem cells (MSCs) have seen a surge in clinical trials over 20 years.
• While safe, MSC therapy's therapeutic success is inconsistent.
• Variability in MSC products arises from donor differences, manufacturing, and diverse tissue sources.

Purpose of the Study:

• To review existing data on MSC source variability.
• To specifically compare MSCs from bone marrow, adipose tissue, and extraembryonic tissues.
• To discuss the implications of these differences for research and clinical use.

Main Methods:

• Literature review of preclinical and clinical studies.
• Focus on comparative studies of MSCs from bone marrow, adipose tissue, and extraembryonic tissues.
• Analysis of MSC functions including differentiation, hematopoietic support, immunomodulation, and paracrine effects.

Main Results:

• Preclinical data indicate biological differences between MSC sources.
• Direct comparative studies are relatively rare.
• Bone marrow MSCs (BMMSCs) usage in trials has decreased significantly since 2008.

Conclusions:

• Tissue-specific differences in MSC function exist and are critical.
• Understanding these differences is essential for optimizing MSC manufacturing and clinical implementation.
• Further research comparing MSC sources is needed to guide therapeutic development.